Changing the Indian Culture in Reporting Adverse Drug Reactions

May 29, 2011

DUBAI, UAE, May 29, 2011 /PRNewswire/ — Adverse Drug Reactions (ADRs)
are the sixth global leading cause of death among hospitalised patients and
the incidence of serious ADRs in hospitalised patients is 6.7 per cent (Joshi
et al).

India is the world’s second most populated country with over one billion
potential drug consumers, and a value of US $ 1 billion worth of clinical
trials, therefore it is very important to focus the attention of the medical
community on the importance of the adverse drug reporting to ensure maximum
patient health.

Dr. Viraj Suvarna, Medical Director at Boehringer Ingelheim who is
speaking at the Pharmacovigilance India Summit has said that while
multinational Pharmaceutical companies which operate in India clearly have
very stringent adverse event reporting requirements, doctors are reluctant to
report adverse events.

“Doctors in India don’t really understand the difference between an
adverse event and an adverse drug reaction. So they believe that they need to
report only if that particular event has a causal relationship to that
product in question. Despite the fact that we’ve trained so many doctors over
so many years, one will still find them to be a little uneducated or a little
hesitant to report because sometimes they feel that they could land into a
medical-legal complication because once they report, then they think that
that report will be processed and it could go against them”, added Dr Suvarna.

This culture of reluctance in reporting is now changing as The Ministry
of Health in India has launched a complete roadmap for a proactive
pharmacovigilance system which will increase the awareness about the benefits
of adverse event reporting.

This programme is called the National Pharmacovigilance Programme and it
is funded by the WHO to foster the reporting culture in India and make sure
that people are receiving safe medicine.

This first edition of Pharmacovigilance India taking place from 27-29
June 2011
at the Hilton Mumbai International Airport will explore the
National Pharmacovigilance Programme in further detail and provide an
opportunity for industry stakeholders to meet, network, do business and share
industry best-practices. Pharmacovigilance India Summit features informative
presentations and case-studies from high profile speakers, including Dr. Y.
K. Gupta
, National Coordinator of Pharmacovigilance Programme of India and
other key speakers from organisations such as International Society of
Pharmacovigilance, UK, Bayer Healthcare Global R & D Centre, China,
Boehringer Ingelheim, Baxter Healthcare, Asia Pacific, Takeda Pharmaceuticals
International, USA, Panacea Biotec, Wockhardt, Novartis Healthcare, Astellas
Pharma, India, Bayer Healthcare, UCB, India, and Biocon, India.

For more information, visit http://www.iqpc.com and

About International Quality and Productivity Centre (IQPC) Middle East:

For over thirty years, IQPC has helped the world’s leading corporations
solve their business challenges through the sharing of practical industry
solutions and global best practice. In the process, the company has built a
formidable reputation for quality and value. During this time, the Middle
most progressive companies have benefited from IQPC’s unrivalled
global reach, which has connected international expertise with regional and
local leaders. For more information, visit http://www.iqpc.ae

    For more information, please contact
    Jihan Mohammed
    Marketing Manager
    International Quality and Productivity Centre Middle East
    T: +971-4-364-2975
    F: +971-4-363-1938


Source: newswire

comments powered by Disqus